Conmind MedTech Files for IPO Following 2023 Global MedTech Rising Star Award

May 05, 2024 00:29 CST Updated 00:29

Conmind

Cardiovascular and Cerebrovascular Interventional Products R&D and Manufacturer

Si YuMedTech selected a group of outstanding enterprises and products from 2023 at the beginning of 2024.Among themCONMINDThe company wasGrant“2023Global MedTech Newcomer Award（2023 Global MedTech Rising Star Award）”。

The reason for winning is:The company has successfully developed a number of innovative interventional devices,HaloChord^®Transcatheter Mitral Chordae Repair SystemTwo sets of artificial tendons can be implanted simultaneously in one capture, and the length of the artificial tendons can be repeatedly and precisely adjusted, making the surgery more efficient, accurate, and the anchoring more secure.J-Tube™ Flow Diverter StentThe full silk imaging design provides superior visibility, and the small delivery system can treat distal small vessel aneurysms. The rounded ends of the stent reduce vascular irritation. Follow-up data after surgery have also preliminarily demonstrated the safety and efficacy of these two devices.

On August 21, 2023, Conmind announced the completion of a nearly RMB 100 million Series B financing round. This round was jointly invested by Turing Asset Management, Zhuhai High-Tech Investment, Chengdu Chuanghe Ruixin, and Guochuang Qinzhi Angel Fund. The funds raised will support the clinical and pre-commercialization advancement of the company's key innovative cardiovascular and cerebrovascular products.

Today, Siyu introduces this innovative company to the readers.

# Company Introduction

Conmind Medical Group(Abbreviation: "CONMIND") was established in 2020 as an innovative high-tech medical device company specializing in the research, development, production, and sales of cardiovascular and cerebrovascular interventional products. The company’s layoutNeurointerventionAndStructural Heart DiseaseTwo Major Fields: Focused on Uncovering Innovative Interventional Treatment Products in Cardiac, Cerebrovascular, and Pan-Vascular Areas. The Neurointerventional Product Pipeline Concentrates on Comprehensive Aneurysm Treatment Solutions, While Cardiac Intervention Products Deeply Cultivate the Mitral and Tricuspid Valve Repair Fields. Conmind, as a "Simultaneous Treatment of Heart and Brain"Enterprises, the market space is huge."

# Corporate Structure

1. Conmind Medical Technology (Shenzhen) Co., Ltd.

Focus onNeurointerventionProduct development, production, and sales. Equipped with advanced laboratories, Class 10,000 cleanrooms, fully functional medical device production equipment, stable and mature process technology, R&D capabilities, and an experienced R&D and sales team. The company possesses comprehensive core development skills and precision manufacturing techniques for the entire range of neurointerventional products, continuously achieving innovative breakthroughs in the cerebrovascular field.

2. HANXIN MEDICAL TECHNOLOGY (SHENZHEN) CO., LTD.

With profoundStructural Heart DiseaseTechnical沉淀, committed to the full set of interventional treatment solutions for mitral and tricuspid valves, accelerating the application of breakthrough interventional devices in research and clinical settings. It has an independent R&D and production base, with a high-end laboratory recognized by CNAS, a 10,000-level cleanroom, fully-equipped medical device production equipment, and complete independent R&D, testing, production, and sales capabilities.

3. Huaxin Technology (Shenzhen) Co., Ltd.

Specializing inSmall Animal Interventional TherapyResearch and innovate interventional treatment devices, and establish a training center for small animal cardiac specialty interventional treatment in China. Unite and collaborate with various clinical diagnosis and treatment centers and equipment manufacturers to share more advanced interventional treatment solutions. Strive to become a pioneer in the field of animal interventional treatment, and explore a more professional, standardized, and healthier new future for the animal healthcare industry.

# Introduction of Founders and Core Team

Introduction of the Founder:

According to Qichacha, its founder and CEO isHui Huang。

Huang Hui has rich experience in interventional product management, start-up company growth, hospital expert resources, and dealer networks. He has served as the National Sales Manager of China for Broncus Medical, Marketing Director and Direct Sales Manager of Huayi Shengjie, and Regional Manager of Lifetech Scientific. During his tenure in managing the sales department, the products he managed grew to rank first or second in market share within their respective categories.

Introduction of Core Team Members:

Zeng Zheng:

Former Deputy Chief Physician of Fuwai Hospital, Chinese Academy of Medical Sciences, Founder and Chairman of Beijing Huayi Shengjie Technology Co., Ltd.Awarded "First Prize for Scientific and Technological Progress in the Ministry of Health for Research and Application of Interventional Radiology Techniques in Cardiovascular Diseases", "Second Prize for National Scientific and Technological Progress for Research and Application of Interventional Treatment Techniques in Cardiovascular Diseases", and "Second Prize for National Scientific and Technological Progress for Research and Application of New Techniques in Interventional Treatment of Structural Heart Diseases".

Tian Zeng:

With forward-looking vision and abundant expert and social resources, they are the co-founders of Conmind Medical and Hengxin Medical. They formerly served as the Sales Director of Huayi Shengjie, establishing a complete sales and market system, successfully capturing 30% of the congenital heart disease market share and 70% of the PFO market share.

# Product Introduction

1. Neurointervention

1. J-Tube™ Flow Diverter Stent